All Publications

Publications for all Oxford Principal Investigators within the CAMS Oxford Institute are included here, please use the search functions for publications related to specific Principal Investigators.

Amine oxidase 3 is a novel pro-inflammatory marker of oxidative stress in peritoneal endometriosis lesions

Thézénas M-L. et al, (2020), Scientific Reports, 10

Hand-foot-and-mouth disease virus receptor KREMEN1 binds the canyon of Coxsackie Virus A10

Zhao Y. et al, (2020), Nature Communications, 11

TEX264 coordinates p97- and SPRTN-mediated resolution of topoisomerase 1-DNA adducts

Fielden J. et al, (2020), Nature Communications, 11

Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel

Adams ER. et al, (2020), Wellcome Open Research, 5, 139 - 139

Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent COVID-19 patients

DONG T., (2020), BioRxiv

SAMHD1-mediated dNTP degradation is required for efficient DNA repair during antibody class switch recombination.

Husain A. et al, (2020), The EMBO journal

Longitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild disease.

Zhao Y. et al, (2020), JCI insight

An evidence-based framework for priority clinical research questions for COVID-19.

Harris C. et al, (2020), Journal of global health, 10

A novel scoring system for prediction of disease severity in COVID-19

DONG TAO., (2020), Frontiers in Cellular and Infection Microbiology, section Virus and Host

Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review.

Dagens A. et al, (2020), BMJ (Clinical research ed.), 369

Human cancer germline antigen-specific cytotoxic T cell-what can we learn from patient.

Abd Hamid M. et al, (2020), Cellular & molecular immunology

Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.

Wang Y. et al, (2020), Trials, 21

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study.

Docherty AB. et al, (2020), BMJ (Clinical research ed.), 369

Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?

Cheung VTF. et al, (2020), British Journal of Cancer

Compassionate drug (mis)use during pandemics: lessons for COVID-19 from 2009.

Rojek A. et al, (2020)

Inflammatory Bowel Disease Through the Lens of Single-cell RNA-seq Technologies.

Corridoni D. et al, (2020), Inflammatory bowel diseases

Lassa fever in pregnancy: a systematic review and meta-analysis

Kayem ND. et al, (2020), Transactions of The Royal Society of Tropical Medicine and Hygiene, 114, 385 - 396

Longitudinal profiling of cytokines and chemokines in COVID-19 reveals inhibitory mediators IL-1Ra and IL-10 are associated with disease severity while elevated RANTES is an early predictor of mild disease

DONG TAO. et al, (2020), Preprint with Lancet

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.

Cao B. et al, (2020), The New England journal of medicine, 382, 1787 - 1799

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.

Wang Y. et al, (2020), Lancet (London, England), 395, 1569 - 1578